Corneal Endothelial Cell Density Changes In Healthy Subjects, When Administered ISV-403 for 5 Days
NCT01120418
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
120
Enrollment
INDUSTRY
Sponsor class
Conditions
Healthy
Interventions
DRUG:
Besifloxacin Ophthalmic Suspension 0.6%
Sponsor
Bausch & Lomb Incorporated